Logo image of OGI

ORGANIGRAM HOLDINGS INC (OGI) Stock Fundamental Analysis

NASDAQ:OGI - Nasdaq - CA68620P7056 - Common Stock - Currency: USD

1.31  +0.02 (+1.55%)

After market: 1.3196 +0.01 (+0.73%)

Fundamental Rating

2

OGI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of OGI have multiple concerns. OGI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year OGI has reported negative net income.
OGI had a positive operating cash flow in the past year.
OGI had negative earnings in each of the past 5 years.
OGI had negative operating cash flow in 4 of the past 5 years.
OGI Yearly Net Income VS EBIT VS OCF VS FCFOGI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

With a decent Return On Assets value of -11.14%, OGI is doing good in the industry, outperforming 69.73% of the companies in the same industry.
OGI has a better Return On Equity (-14.85%) than 73.51% of its industry peers.
Industry RankSector Rank
ROA -11.14%
ROE -14.85%
ROIC N/A
ROA(3y)-32.3%
ROA(5y)-30.36%
ROE(3y)-36.4%
ROE(5y)-36.38%
ROIC(3y)N/A
ROIC(5y)N/A
OGI Yearly ROA, ROE, ROICOGI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

OGI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OGI Yearly Profit, Operating, Gross MarginsOGI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

OGI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OGI has been increased compared to 1 year ago.
OGI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for OGI is higher compared to a year ago.
OGI Yearly Shares OutstandingOGI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
OGI Yearly Total Debt VS Total AssetsOGI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -0.49, we must say that OGI is in the distress zone and has some risk of bankruptcy.
OGI has a Altman-Z score (-0.49) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.10 indicates that OGI is not too dependend on debt financing.
OGI has a Debt to Equity ratio (0.10) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -0.49
ROIC/WACCN/A
WACC8.48%
OGI Yearly LT Debt VS Equity VS FCFOGI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

OGI has a Current Ratio of 4.92. This indicates that OGI is financially healthy and has no problem in meeting its short term obligations.
OGI's Current ratio of 4.92 is fine compared to the rest of the industry. OGI outperforms 64.32% of its industry peers.
OGI has a Quick Ratio of 3.37. This indicates that OGI is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of OGI (3.37) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.92
Quick Ratio 3.37
OGI Yearly Current Assets VS Current LiabilitesOGI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for OGI have decreased strongly by -65.08% in the last year.
OGI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.84%.
Measured over the past years, OGI shows a very strong growth in Revenue. The Revenue has been growing by 67.11% on average per year.
EPS 1Y (TTM)-65.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)10.84%
Revenue growth 3Y23.02%
Revenue growth 5Y67.11%
Sales Q2Q%20.05%

3.2 Future

OGI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.66% yearly.
Based on estimates for the next years, OGI will show a quite strong growth in Revenue. The Revenue will grow by 16.15% on average per year.
EPS Next Y48.8%
EPS Next 2Y31.91%
EPS Next 3Y25.11%
EPS Next 5Y17.66%
Revenue Next Year3.82%
Revenue Next 2Y23.97%
Revenue Next 3Y21.31%
Revenue Next 5Y16.15%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
OGI Yearly Revenue VS EstimatesOGI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
OGI Yearly EPS VS EstimatesOGI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OGI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OGI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OGI Price Earnings VS Forward Price EarningsOGI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OGI Per share dataOGI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as OGI's earnings are expected to grow with 25.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.91%
EPS Next 3Y25.11%

More info and screens

0

5. Dividend

5.1 Amount

OGI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORGANIGRAM HOLDINGS INC

NASDAQ:OGI (2/21/2025, 8:00:01 PM)

After market: 1.3196 +0.01 (+0.73%)

1.31

+0.02 (+1.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11 2025-02-11/bmo
Earnings (Next)05-12 2025-05-12
Inst Owners6.49%
Inst Owner Change-87.11%
Ins Owners2.59%
Ins Owner ChangeN/A
Market Cap165.35M
Analysts77.78
Price Target2.34 (78.63%)
Short Float %3.02%
Short Ratio3.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.53%
Min EPS beat(2)-127.72%
Max EPS beat(2)136.78%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.29%
Min Revenue beat(2)2.96%
Max Revenue beat(2)3.61%
Revenue beat(4)2
Avg Revenue beat(4)0.03%
Min Revenue beat(4)-4.45%
Max Revenue beat(4)3.61%
Revenue beat(8)3
Avg Revenue beat(8)-2.49%
Revenue beat(12)6
Avg Revenue beat(12)0%
Revenue beat(16)8
Avg Revenue beat(16)-0.33%
PT rev (1m)-0.58%
PT rev (3m)-13.76%
EPS NQ rev (1m)-100%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-125.47%
EPS NY rev (3m)-125.47%
Revenue NQ rev (1m)5.34%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-4.79%
Revenue NY rev (3m)29.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.47
P/FCF N/A
P/OCF 60.62
P/B 0.77
P/tB 0.79
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.02
OCFY1.65%
SpS0.89
BVpS1.71
TBVpS1.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.14%
ROE -14.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.3%
ROA(5y)-30.36%
ROE(3y)-36.4%
ROE(5y)-36.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.19%
Cap/Sales 3.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.92
Quick Ratio 3.37
Altman-Z -0.49
F-Score3
WACC8.48%
ROIC/WACCN/A
Cap/Depr(3y)118.74%
Cap/Depr(5y)166.77%
Cap/Sales(3y)18.54%
Cap/Sales(5y)32.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-65.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y48.8%
EPS Next 2Y31.91%
EPS Next 3Y25.11%
EPS Next 5Y17.66%
Revenue 1Y (TTM)10.84%
Revenue growth 3Y23.02%
Revenue growth 5Y67.11%
Sales Q2Q%20.05%
Revenue Next Year3.82%
Revenue Next 2Y23.97%
Revenue Next 3Y21.31%
Revenue Next 5Y16.15%
EBIT growth 1Y-1.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year133.45%
EBIT Next 3Y49.29%
EBIT Next 5Y34.15%
FCF growth 1Y97.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y109.99%
OCF growth 3YN/A
OCF growth 5YN/A